Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study.

BMC Pulm Med · 2023 · PMC10463591 · PMID 37641042

Europe PMC DOI

hedged sentences

0.6300

closest p · 12.6× alpha

0.6300

boldest claim

The sentences

did not reach statistical significanceP = 0.63not close (p > 0.1)

Ventilator free days (VFDs) and length of stay (LOS) Patients who received early methylprednisolone had shorter VFDs than the dexamethasone group; however, it did not reach statistical significance (-0.20; CI: -0.99 – 0.60; P = 0.63).

also in 111,027 other papers

failed to reach statistical significanceno p-value reported

Conclusions Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.